- Home
- SYM vs MDGL Comparison
SYM vs MDGL Comparison
Compare SYM & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYM
- MDGL
- Stock Information
- Founded
- SYM 2005
- MDGL 2011
- Country
- SYM United States
- MDGL United States
- Employees
- SYM N/A
- MDGL N/A
- Industry
- SYM Industrial Machinery/Components
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- SYM Industrials
- MDGL Health Care
- Exchange
- SYM Nasdaq
- MDGL Nasdaq
- Market Cap
- SYM 5.4B
- MDGL 6.1B
- IPO Year
- SYM N/A
- MDGL N/A
- Fundamental
- Price
- SYM $47.75
- MDGL $432.22
- Analyst Decision
- SYM Buy
- MDGL Strong Buy
- Analyst Count
- SYM 12
- MDGL 10
- Target Price
- SYM $41.60
- MDGL $474.67
- AVG Volume (30 Days)
- SYM 1.6M
- MDGL 378.1K
- Earning Date
- SYM 08-06-2025
- MDGL 10-30-2025
- Dividend Yield
- SYM N/A
- MDGL N/A
- EPS Growth
- SYM N/A
- MDGL N/A
- EPS
- SYM N/A
- MDGL N/A
- Revenue
- SYM $2,193,031,000.00
- MDGL $515,547,000.00
- Revenue This Year
- SYM $25.94
- MDGL $394.12
- Revenue Next Year
- SYM $20.25
- MDGL $57.74
- P/E Ratio
- SYM N/A
- MDGL N/A
- Revenue Growth
- SYM 35.75
- MDGL 3421.98
- 52 Week Low
- SYM $16.32
- MDGL $200.63
- 52 Week High
- SYM $64.16
- MDGL $457.16
- Technical
- Relative Strength Index (RSI)
- SYM 48.34
- MDGL 62.68
- Support Level
- SYM $46.40
- MDGL $425.00
- Resistance Level
- SYM $51.27
- MDGL $457.16
- Average True Range (ATR)
- SYM 2.27
- MDGL 14.38
- MACD
- SYM 0.15
- MDGL -2.84
- Stochastic Oscillator
- SYM 56.38
- MDGL 47.00
About SYM Symbotic Inc.
Symbotic Inc is an automation technology company that develops technologies to improve operating efficiencies in modern warehouses. The group develops, commercializes, and deploys end-to-end technology solutions that dramatically improve supply chain operations. Th company also automates the processing of pallets and cases in large warehouses or distribution centers for some of the retail and wholesale companies in the world. The company operates in two geographical regions the United States and Canada. Key revenue is generated from the United States.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.